Genetic Technologies' FY 2014 Q1 Revenues Drop 17 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Genetic Technologies said on Thursday that receipts from customers for its first quarter of Fiscal Year 2014 dropped 17 percent.

For the three months ended Sept. 30, receipts totaled A$1.0 million (US$945,000) down from $A1.2 million, a year ago. The downtick occurred despite a record number of test samples for its flagship non-familial breast cancer risk assessment test called BrevaGen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.